Concert Pharmaceuticals (NASDAQ: CNCE) recently received a number of ratings updates from brokerages and research firms:
- 3/6/2019 – Concert Pharmaceuticals was upgraded by analysts at BidaskClub from a “buy” rating to a “strong-buy” rating.
- 3/5/2019 – Concert Pharmaceuticals was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “strong sell” rating. According to Zacks, “Concert Pharmaceuticals Inc. is a biopharmaceutical company. It is focused on applying its DCE Platform (R) to create novel small molecule drugs. The Company manufactures drugs in various therapeutic areas such as hot flashes, HIV, renal hepatic, neuropathic pain, MRSA infection, and schizophrenia, multiple tumors, and hyperparathyroidism. Concert Pharmaceuticals Inc. is based in United States. “
- 3/1/2019 – Concert Pharmaceuticals was downgraded by analysts at TheStreet from a “c-” rating to a “d” rating.
- 3/1/2019 – Concert Pharmaceuticals had its “buy” rating reaffirmed by analysts at HC Wainwright. They wrote, “Our price target of $26/share is comprised of $16.38 from CTP-543 in AA + $3.04 from AVP-786 in AD agitation + $6.38 in cash and is based on a discounted cash flow analysis (2019-2026) using a 12% discount rate and 1% growth rate, in line with the expected discount and growth parameters of a development stage biotechnology company. Risks to our investment thesis and target price include: (1) failure in clinical studies; (2) failure to secure regulatory approval; and (3) smaller than anticipated commercial opportunity due to market size, competition, and pricing.””
Shares of CNCE opened at $16.18 on Friday. The stock has a market capitalization of $380.70 million, a price-to-earnings ratio of -6.74 and a beta of 1.03. Concert Pharmaceuticals Inc has a 52 week low of $10.80 and a 52 week high of $24.19.
Concert Pharmaceuticals (NASDAQ:CNCE) last issued its quarterly earnings results on Thursday, February 28th. The biotechnology company reported ($0.89) EPS for the quarter, missing analysts’ consensus estimates of ($0.74) by ($0.15). Concert Pharmaceuticals had a negative return on equity of 29.33% and a negative net margin of 533.31%. As a group, sell-side analysts expect that Concert Pharmaceuticals Inc will post -3.32 EPS for the current year.
Concert Pharmaceuticals, Inc operates as a clinical stage biopharmaceutical company. The company discovers and develops novel small molecule drugs for use in the treatment of various pulmonary diseases, including autoimmune and inflammatory diseases, and central nervous systems disorders. Its product candidates include AVP-786, a combination of deudextromethorphan and an ultra-low dose of quinidine, which is in Phase 3 clinical trials for the treatment of neurologic and psychiatric disorders, including agitation associated with Alzheimer's disease; CTP-730, a deuterated analog of apremilast that has completed the Phase 1 clinical trials for the treatment of inflammation or cancer; JZP-386, which has completed the Phase 1 clinical trials for the treatment of patients with narcolepsy; and CTP-543, which is in Phase 1 clinical trials for use in the treatment of alopecia areata.
Further Reading: Buy-Side Analysts
Receive News & Ratings for Concert Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Concert Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.